Navigation Links
NPS Pharmaceuticals Reports 2007 Financial Results
Date:3/13/2008

ceuticals is developing specialty therapeutics for gastrointestinal and endocrine disorders with high unmet medical need. The company is currently advancing two late-stage programs: GATTEX(TM) (teduglutide) is in Phase 3 clinical development for intestinal failure associated with short bowel syndrome and NPSP558 (parathyroid hormone 1-84 [rDNA origin] injection) is in Phase 2 clinical development as a hormone therapy for hypoparathyroidism. NPS has also completed a Phase 3 osteoporosis study for PREOS(R) (parathyroid hormone 1-84 [rDNA origin] injection). NPS complements its internal programs with strategic partnerships with Amgen, GlaxoSmithKline, Kirin, and Nycomed. Additional information is available at http://www.npsp.com.

Statements made in this press release, which are not historical in nature, constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements are based on the company's current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Risks associated to NPS's business include, but are not limited to, the risk of successfully executing its preclinical and clinical studies and gaining marketing approvals for GATTEX and NPSP558, the risks associated with the company's auction-rate securities, the risk that the steps NPS has taken or is taking to address the material weakness will be adequate or that future material weaknesses or control deficiencies will be identified, as well as other factors expressed in NPS's periodic filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K and Form 10-Qs. All information in this press release is as of the date of this release and NPS undertakes no duty to update this information.


'/>"/>

SOURCE NPS Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
2. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
3. Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference
4. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
5. Sagent Pharmaceuticals Launches Cefazolin for Injection, USP
6. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs
8. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
9. Onyx Pharmaceuticals to Present at Cowen and Company Health Care Conference
10. Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
11. VIA Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2015)... ... July 23, 2015 , ... One hundred years ago this year, ... Model Aeroplane Competition, with hopes of winning the Henry S. Villard Trophy. The Academy ... Participants will have the opportunity to build a Free Flight fantasy club worthy of ...
(Date:7/23/2015)... ... 23, 2015 , ... July 23, 2015, Chicago - Advances ... options with fewer side effects, according to Erik P. Sulman, MD, PhD, associate ... the American Brain Tumor Association (ABTA) National Patient and Family Conference in Chicago, ...
(Date:7/23/2015)... - Portage Biotech Inc. ("Portage") (OTC Market: PTGEF, Canadian ... Limited (Biohaven), are pleased to announce that Biohaven ... with the U.S. Food and Drug Administration (FDA) ... 54% equity interest in Biohaven, a private company. ... and Biohaven has entered into an exclusive worldwide ...
(Date:7/23/2015)... -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS ), ... and the general public to its Annual Shareholder Meeting ... 31, 2015. The meeting will be held at the ... San Diego, California 92121.   ... available. Please use the following link to register for ...
Breaking Biology Technology:Academy of Model Aeronautics to Start Online Fantasy Flight Competition 2Radiation Oncology Advances Improve Safety and Efficacy of Treatment for Brain Tumors 2Radiation Oncology Advances Improve Safety and Efficacy of Treatment for Brain Tumors 3Portage's Biohaven Announces IND Filing for BHV-0223 for Phase 1 Clinical Testing 2Portage's Biohaven Announces IND Filing for BHV-0223 for Phase 1 Clinical Testing 3Portage's Biohaven Announces IND Filing for BHV-0223 for Phase 1 Clinical Testing 4OncoSec to Webcast Annual Meeting of Stockholders 2
... fast and easy detection of mycoplasma,contamination , ... Staggs ,Genetic Applications LLC , Heinz Miller ,Stratagene , ... potency of transfection reagents. 1 Cells must be ... ,transfection reagent and ...
... using LipoTAXI transfection reagent , Peter ... Karmiol ,Clonetics Corporation, Walkersville, Maryland , LipoTAXI ... that offers,low cellular toxicity and high transfection ... is described for optimizing the amounts of ...
... transfection reagent: A proven choice , ... transfection reagent offers,improved, ... growing in,suspension. In this article, we summarize the ... LipoTAXI reagent. Optimizing transfection,conditions is a critical, preliminary ...
Cached Biology Technology:Mycoplasma Contamination Reduces the Effect of Lipid-Mediated Transfection,of Mammalian Cells 2Mycoplasma Contamination Reduces the Effect of Lipid-Mediated Transfection,of Mammalian Cells 3Low-Toxicity, Lipid-Mediated Transfection of Mammalian Cells 2Low-Toxicity, Lipid-Mediated Transfection of Mammalian Cells 3Low-Toxicity, Lipid-Mediated Transfection of Mammalian Cells 4Low-Toxicity, Lipid-Mediated Transfection of Mammalian Cells 5Versatile Transfection Reagent Offers Low Toxicity and Consistent,Performance 2Versatile Transfection Reagent Offers Low Toxicity and Consistent,Performance 3Versatile Transfection Reagent Offers Low Toxicity and Consistent,Performance 4Versatile Transfection Reagent Offers Low Toxicity and Consistent,Performance 5Versatile Transfection Reagent Offers Low Toxicity and Consistent,Performance 6Versatile Transfection Reagent Offers Low Toxicity and Consistent,Performance 7
(Date:7/21/2015)... Sweden , July 21, 2015 Today, ... FPC1025. Already received as well as expected revenues in 2015 that ... in FPC,s communicated revenue guidance of approximately 2,200 MSEK for 2015. ... is a leading smartphone manufacturer in China ... selected FPC1 02 5 for Axon ...
(Date:7/13/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... focused on the growing mobile commerce market, announced ... for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD AND SYSTEM. ... secure method to make payments.  With this patent, ... with its groundbreaking voice-direct payment patent application, with ...
(Date:7/8/2015)... -- Summary Pancreatic cancer is the 12th most ... a mortality rate of 10.9 deaths per 100,000 people ... has highlighted a significant need for new and improved ... the current market. A highly active pancreatic cancer ... types and mechanisms of action, which provides a striking ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
... natural selection favours traits that enhance dispersal of ... this theory, however, is relatively scarce. A study ... Biological and Environmental Sciences of the University of ... evolution of traits facilitating dispersal in an outer ...
... much iron is toxic, and can cause fatal organ failure. ... also be maintained. In a study published today in ... (EMBL) in Heidelberg, Germany, have discovered that a group of ... and as such are essential for cell survival. More specifically, ...
... ANN ARBOR, Mich.---In one of the first human studies ... the controversial chemical Bisphenol A, or BPA, may be related ... the researchers are quick to point out that these results ... documented adverse effects of BPA on semen in rodents, but ...
Cached Biology News:UH: Insular evolution: Large and big-footed voles in an outer archipelago 2Supply and demand 2Sperm may be harmed by exposure to BPA, study suggests 2
For the differentiation of mouse embryonic stem cells tooligodendrocytes....
Preadipocyte factor-1 [Pref-1, DLK-1], C-terminal...
IC50: 35 ng/ml · Limit of detection: 8 ng/ml...
, Glycerol 30%...
Biology Products: